Therefore, SH2B3/Lnk mutation-mediated interference of proliferation or inflammatory pathway downregulation may affect PAD/CAD progression based on pleiotropic involvement of the Lnk protein in stem/precursor proliferation, integrin signaling, platelet thrombus formation, and endothelial activation [5,86,87]. Here, SH2B3 is linked to peripheral arterial disease.